Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Drug combo quiet the tremors Parkinson's patients still feel?

NCT ID NCT07804615

Disease control Sponsor: Vima Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This phase 2 trial tests an experimental drug called VIM0423 in adults with Parkinson's disease whose tremor does not respond well to standard dopaminergic therapy. Researchers want to see if VIM0423 can reduce tremor severity, improve daily function and quality of life, and be safe and tolerable. Participants will receive either VIM0423 or a placebo, and the study will measure changes in tremor using a standard Parkinson's rating scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VIM0423, a combination of two experimental drugs (VMA-1001 and VMA-1002)
What this could lead to
If it works, VIM0423 could offer a new option for people with Parkinson's whose tremor does not improve enough with current dopaminergic therapy, potentially improving daily function and quality of life.
What could go wrong
This is an early phase 2 study with only 80 participants, so results may not hold up in larger groups. The drug may not outperform placebo, and side effects are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening). * Diagnosis of clinically probable or clinically established idiopathic Parkinson's disease (PD) at Visit 1 (Screening) established by the MDS 2015 criteria which must include tremor as one of the cardinal characteristics. * Cohort 1: Currently using levodopa (any oral form only) or oral dopamine agonist at a stable dose and regimen of at least 10 weeks prior to Visit 1 (Screening); with no anticipated changes to said therapies for the duration of the study; and on a minimum of 300 mg LEDD. Cohort 2: Individuals who are dopaminergic naïve, as defined by: no prior or ongoing usage of levodopa (in any form) or dopamine agonist (in any form), and no anticipated plans to initiate said therapies for the duration of the study. * The participants must meet protocol-specified requirements for baseline tremor scores. Exclusion Criteria * Currently (within 7 days of Screening) taking any anticholinergic medication. * Prior deep brain stimulation (DBS) or any other form of invasive neurosurgical intervention (including, but not limited to, magnetic resonance-guided focused ultrasound thalamotomy, ablative thalamotomy, gamma knife thalamotomy) Other protocol-specified inclusion and exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (disorder) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain disorder central nervous system disorder movement disorder nervous system disorder neurodegenerative disease Parkinson disease parkinsonian disorder Tremor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease (disorder)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    30 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Vima Site #002

    Farmington Hills, Michigan, 48334, United States

  • Vima Site #007

    Olney, Maryland, 20832, United States

    Contact Email: •••••@•••••

  • Vima Site #008

    Miami, Florida, 33176, United States

    Contact Email: •••••@•••••

  • Vima Site #014

    Albuquerque, New Mexico, 87106, United States

    Contact Email: •••••@•••••

  • Vima Site #015

    Spokane, Washington, 99202, United States

    Contact Email: •••••@•••••

  • Vima Site #016

    Memphis, Tennessee, 38157, United States

    Contact Email: •••••@•••••

  • Vima Site #023

    Kirkland, Washington, 98034, United States

    Contact Email: •••••@•••••

  • Vima Site #024

    New York, New York, 10019, United States

    Contact Email: •••••@•••••

  • Vima Site #039

    Scottsdale, Arizona, 85251, United States

    Contact Email: •••••@•••••

  • Vima Site #041

    Overland Park, Kansas, 66211, United States

    Contact Email: •••••@•••••

  • Vima Site #043

    Baltimore, Maryland, 21237, United States

    Contact Email: •••••@•••••

  • Vima Site #045

    Decatur, Georgia, 30030, United States

    Contact Email: •••••@•••••

  • Vima Site #046

    Naples, Florida, 34105, United States

    Contact Email: •••••@•••••

  • Vima Site #047

    Atlanta, Georgia, 30328, United States

    Contact Email: •••••@•••••

  • Vima Site #048

    Murrieta, California, 92562, United States

    Contact Email: •••••@•••••

  • Vima Site #049

    Cypress, Texas, 77429, United States

    Contact Email: •••••@•••••

  • Vima Site #050

    Stamford, Connecticut, 06905, United States

    Contact Email: •••••@•••••

  • Vima Site #051

    Canton, Ohio, 44718, United States

  • Vima Site #052

    Patchogue, New York, 11772, United States

    Contact Email: •••••@•••••

  • Vima Site #053

    Palm Beach, Florida, 33407, United States

    Contact Email: •••••@•••••

  • Vima Site #054

    Aventura, Florida, 33180, United States

    Contact Email: •••••@•••••

  • Vima Site #055

    Amherst, New York, 14226, United States

    Contact Email: •••••@•••••

  • Vima Site #058

    Round Rock, Texas, 78681, United States

    Contact Email: •••••@•••••

  • Vima Site #060

    Toronto, Ontario, M5G 2C4, Canada

    Contact Email: •••••@•••••

  • Vima Site #062

    Tampa, Florida, 33602, United States

    Contact Email: •••••@•••••

  • Vima Site #063

    Dallas, Texas, 75243, United States

    Contact Email: •••••@•••••

  • Vima Site #064

    Scottsdale, Arizona, 85258, United States

    Contact Email: •••••@•••••

  • Vima Site #065

    Altamonte Springs, Florida, 32714, United States

    Contact Email: •••••@•••••

  • Vima Site #066

    Arlington, Virginia, 22205, United States

    Contact Email: •••••@•••••

  • Vima Site #067

    Raleigh, North Carolina, 27607, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.